Because Nlrp3 deletion reduces mortality and sepsis-induced end-organ damage, such as muscle failure [195], cardiomyopathy [250,251] and acute lung injury, pharmacological NLRP3 inhibition might be beneficial in sepsis. Here, NLRP3 is linked to cardiomyopathy.